We develop innovative therapeutics to protect and improve the vision of patients with a range of retinal diseases and conditions.
Learn More

ONL Therapeutics is a clinical-stage biopharmaceutical company committed to helping patients see the future.

Clinical Trials

The company’s lead therapeutic candidate, ONL1204, is a first-in-class small peptide that is being studied in multiple diseases.

Science

Our primary scientific focus is Fas-mediated signaling, initiated by the activation of the Fas receptor at the cell surface and implicated in a variety of diseases.

Category: News Items

  • Applications for Neuroprotection: The Next Therapeutic Category in Retina Medicine

    Applications for Neuroprotection: The Next Therapeutic Category in Retina Medicine Retina Today – October 2014By Pravin U. Dugel, M.D. Leading retinal specialist and industry opinion leader Pravin U. Dugel, MD, discusses ONL Therapeutics’ core technology and its significant potential to treat retinal disease. Read the Article

  • ONL Therapeutics Wins Emerging Company Showcase at MichBio Expo

    ONL Therapeutics Wins Emerging Company Showcase at MichBio Expo Crain’s Detroit – 10/02/14by Tom HendersonONL Therapeutics was named the first place winner in the Emerging Company Showcase at the MichBio Expo winning a $2,500 first prize.  See article in Crain’s Detroit below: Read the Article

  • ONL ANNOUNCES LEADERSHIP CHANGES

    ONL ANNOUNCES LEADERSHIP CHANGES ONL ANNOUNCES LEADERSHIP CHANGESOctober 29, 2013 Ann Arbor, Mich. (October 29, 2013) — ONL Therapeutics today announced the appointments of John Freshley as Chief Executive Officer and Anna Schwendeman as Vice President of Preclinical Development. These appointments follow the sad loss of Co-Founder and former CEO Raili Kerppola to adrenal cancer…

  • ONL RECEIVES ORPHAN DRUG DESIGNATION FOR ONL-101 IN RETINAL DETACHMENT

    ONL RECEIVES ORPHAN DRUG DESIGNATION FOR ONL-101 IN RETINAL DETACHMENT ONL RECEIVES ORPHAN DRUG DESIGNATION FOR ONL-101 IN RETINAL DETACHMENTMarch 19, 2013 Ann Arbor, Mich. (March 19, 2013) — ONL Therapeutics today announced that it has received an orphan drug designation form the FDA for ONL-101 in its lead indication of retinal detachment. Orphan drug…